These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28283779)

  • 1. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.
    Diamond JR; Goff B; Forster MD; Bendell JC; Britten CD; Gordon MS; Gabra H; Waterhouse DM; Poole M; Ross Camidge D; Hamilton E; Moore KM
    Invest New Drugs; 2017 Oct; 35(5):627-633. PubMed ID: 28283779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
    Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
    Kakolyris S; Kouroussis C; Souglakos J; Mavroudis D; Agelaki S; Kalbakis K; Androulakis N; Vardakis N; Vamvakas L; Georgoulias V
    Oncology; 2001; 61(4):265-70. PubMed ID: 11721172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
    Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
    Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
    Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
    Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma.
    Puls LE; Phillips B; Schammel C; Hunter JE; Griffin D
    Med Oncol; 2010 Jun; 27(2):368-72. PubMed ID: 19381891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer.
    Chelariu-Raicu A; Levenback CF; Slomovitz BM; Wolf J; Bodurka DC; Kavanagh JJ; Morrison C; Gershenson DM; Coleman RL
    Int J Gynecol Cancer; 2020 Nov; 30(11):1768-1774. PubMed ID: 33037105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
    Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
    Paik PK; Rudin CM; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R; Markus S; Tyson L; Subzwari S; Kris MG; Krug LM
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1079-85. PubMed ID: 20165849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
    Gronlund B; Engelholm SA; Horvath G; Mäenpää J; Ridderheim M
    Cancer; 2005 Apr; 103(7):1388-96. PubMed ID: 15719439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
    Hotte SJ; Oza A; Winquist EW; Moore M; Chen EX; Brown S; Pond GR; Dancey JE; Hirte HW
    Ann Oncol; 2006 Feb; 17(2):334-40. PubMed ID: 16284058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience.
    Hu CF; Ou YC; Fu HC; Chang Chien CC; Tsai CC; Wu CH; Lin H
    Taiwan J Obstet Gynecol; 2015 Feb; 54(1):43-7. PubMed ID: 25675918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
    Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.
    Rose PG; Sill MW; McMeekin DS; Ahmed A; Salani R; Yamada SD; Wolfson AH; Fusco N; Fracasso PM
    Gynecol Oncol; 2012 Apr; 125(1):158-62. PubMed ID: 22198338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer.
    Beldner MA; Sherman CA; Green MR; Garrett-Mayer E; Chaudhary U; Meyer ML; Kraft AS; Montero AJ
    BMC Cancer; 2007 Dec; 7():231. PubMed ID: 18096059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer.
    Lorusso D; Mainenti S; Pietragalla A; Fusco E; Malaguti P; Masciullo V; Scambia G
    Oncology; 2011; 80(5-6):390-4. PubMed ID: 21829040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
    Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
    Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
    Ramasubbaiah R; Perkins SM; Schilder J; Whalen C; Johnson CS; Callahan M; Jones T; Sutton G; Matei D
    Gynecol Oncol; 2011 Dec; 123(3):499-504. PubMed ID: 21955480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.